Russell Investments Group Ltd. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 11.6% in the first quarter, Holdings Channel.com reports. The fund owned 3,435,093 shares of the company’s stock after selling 449,696 shares during the quarter. Johnson & Johnson comprises 1.2% of Russell Investments Group Ltd.’s holdings, making the stock its 7th largest holding. Russell Investments Group Ltd.’s holdings in Johnson & Johnson were worth $452,809,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Houlihan Financial Resource Group Ltd. acquired a new stake in Johnson & Johnson during the 4th quarter worth $1,376,000. Bowen Hanes & Co. Inc. grew its holdings in Johnson & Johnson by 11.5% during the 4th quarter. Bowen Hanes & Co. Inc. now owns 362,432 shares of the company’s stock worth $52,868,000 after acquiring an additional 37,290 shares during the period. Community Financial Services Group LLC grew its holdings in shares of Johnson & Johnson by 2.6% in the 4th quarter. Community Financial Services Group LLC now owns 25,571 shares of the company’s stock valued at $3,730,000 after buying an additional 645 shares during the period. Chelsea Counsel Co. grew its holdings in shares of Johnson & Johnson by 3.9% in the 4th quarter. Chelsea Counsel Co. now owns 45,344 shares of the company’s stock valued at $6,614,000 after buying an additional 1,693 shares during the period. Finally, Csenge Advisory Group grew its holdings in shares of Johnson & Johnson by 18.7% in the 4th quarter. Csenge Advisory Group now owns 13,480 shares of the company’s stock valued at $1,966,000 after buying an additional 2,127 shares during the period. 67.66% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on JNJ. Raymond James upped their target price on shares of Johnson & Johnson from $153.00 to $157.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. SVB Leerink dropped their target price on shares of Johnson & Johnson from $172.00 to $160.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Wells Fargo & Co raised shares of Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Morgan Stanley upped their target price on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Finally, Barclays upped their target price on shares of Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Johnson & Johnson has a consensus rating of “Buy” and a consensus price target of $163.47.
In other Johnson & Johnson news, Director William D. Perez acquired 500 shares of Johnson & Johnson stock in a transaction dated Friday, March 13th. The stock was purchased at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the acquisition, the director now directly owns 16,030 shares of the company’s stock, valued at $2,046,870.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.27% of the stock is owned by company insiders.
NYSE:JNJ opened at $146.71 on Friday. The company has a current ratio of 1.31, a quick ratio of 1.05 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $389.08 billion, a price-to-earnings ratio of 16.63, a PEG ratio of 3.21 and a beta of 0.71. The firm has a fifty day simple moving average of $146.50 and a two-hundred day simple moving average of $142.23. Johnson & Johnson has a 12 month low of $109.16 and a 12 month high of $157.00.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.03 by $0.27. The business had revenue of $20.69 billion during the quarter, compared to analysts’ expectations of $19.48 billion. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The business’s quarterly revenue was up 3.3% on a year-over-year basis. During the same period last year, the company posted $2.10 earnings per share. Equities analysts predict that Johnson & Johnson will post 7.68 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a dividend of $1.01 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date is Friday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 43.78%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: The limitations of an equal weight rating
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.